Imricor’s Breakthrough iCMR Procedure Marks a Turning Point as Stock Surges 206% Year-on-Year

Key Highlights:

• Amsterdam UMC completes world’s first MRI-guided ventricular ablation using Imricor’s technology
• CE Mark granted for second-gen Vision-MR catheter under EU’s new MDR framework
• Imricor launches European subsidiary and advances NorthStar 3D mapping system
• Q1 2025 ends with US$53.9M cash post A$70M raise; runway extended beyond 11 quarters
• Stock climbs 5% today to $1.47, up 206.25% over 12 months
   

Sydney, 23 April 2025 — In a move that cements its position at the forefront of cardiac innovation, Imricor Medical Systems Inc. (ASX: IMR) has announced a world-first MRI-guided ventricular ablation, completed earlier this month at Amsterdam UMC. The groundbreaking procedure—performed under real-time imaging using Imricor’s proprietary platform—marks a seismic shift in how complex arrhythmias can be treated with greater precision and safety.

The market has responded in kind. Imricor shares climbed 5% to $1.47 today, bringing its 12-month return to a staggering 206.25%, and lifting the company’s market cap to $470.88 million. Its 52-week range now sits between $0.41 and $1.71, reflecting the company’s transformation from a niche medtech innovator to a market-defining disruptor in electrophysiology.

Landmark Clinical Milestone and Regulatory Momentum

The successful “first-in-man” iCMR ventricular ablation procedure on April 10 was a culmination of years of development and strategic collaboration. Imricor CEO Steve Wedan called it a “fantastic start to 2025,” and one that validates the clinical edge of its MRI-compatible Vision-MR ablation catheter and Advantage-MR EP recorder/stimulator system.

Simultaneously, the company secured CE Mark approval for its second-generation Vision-MR catheter under the more rigorous European Medical Device Regulation (MDR). These regulatory tailwinds pave the way for further adoption across Europe, supported by the launch of a dedicated European subsidiary—Imricor BV—in Amsterdam.

Strengthened Financial Position and Strategic Expansion

Imricor’s quarterly report reveals a robust cash balance of US$53.9 million, bolstered by a A$70 million capital raise in March, extending its operational runway for more than 11 quarters. Cash receipts rose 83% year-over-year to US$199k, and while Q1 remained pre-revenue due to clinical trial protocols, sales of consumables surged 385% over the same period in 2024.

The company also expanded its sales team in both Europe and the United States, hired key capital sales personnel, and progressed ethics and start-up approvals for its VISABL-VT trial targeting ventricular tachycardia.

Investor Appetite Grows with Market Validation

Imricor’s performance metrics reflect growing investor confidence. The company has outperformed both its healthcare sector peers (+211.79%) and the ASX 200 index (+203.13%) over the past year. Its average daily volume over the past month has hovered around 569,000 shares, though today’s volume of 274,151 signals steady institutional interest rather than speculative spikes.

Today’s trading range between $1.42 and $1.48, with a VWAP of $1.4545, shows healthy price discovery amid elevated investor optimism. Despite negative EPS of -$0.203 and no dividends issued, investors are clearly betting on Imricor’s unique tech moat and the scaling potential of MRI-guided interventions.

Outlook: From Milestone to Momentum

Looking ahead, Imricor is poised to benefit from tailwinds in both clinical validation and market expansion. Its participation in global trials (including VISABL-AFL for atrial flutter), collaborations with imaging giants Philips and Siemens, and the rollout of the NorthStar 3D mapping system, place the company in a prime position to scale.

With a strengthened balance sheet, regulatory validation, and a first-mover advantage in MRI-guided ablations, Imricor is not just riding the medtech wave—it’s creating it.